JP2020535180A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535180A5
JP2020535180A5 JP2020517814A JP2020517814A JP2020535180A5 JP 2020535180 A5 JP2020535180 A5 JP 2020535180A5 JP 2020517814 A JP2020517814 A JP 2020517814A JP 2020517814 A JP2020517814 A JP 2020517814A JP 2020535180 A5 JP2020535180 A5 JP 2020535180A5
Authority
JP
Japan
Prior art keywords
seq
compound
cancer
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020517814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535180A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/076494 external-priority patent/WO2019063802A1/en
Publication of JP2020535180A publication Critical patent/JP2020535180A/ja
Publication of JP2020535180A5 publication Critical patent/JP2020535180A5/ja
Pending legal-status Critical Current

Links

JP2020517814A 2017-09-29 2018-09-28 抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療 Pending JP2020535180A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17194196.6 2017-09-29
EP17194196 2017-09-29
PCT/EP2018/076494 WO2019063802A1 (en) 2017-09-29 2018-09-28 ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1

Publications (2)

Publication Number Publication Date
JP2020535180A JP2020535180A (ja) 2020-12-03
JP2020535180A5 true JP2020535180A5 (enExample) 2021-11-11

Family

ID=60009481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020517814A Pending JP2020535180A (ja) 2017-09-29 2018-09-28 抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療

Country Status (5)

Country Link
US (1) US20200239559A1 (enExample)
EP (1) EP3687573A1 (enExample)
JP (1) JP2020535180A (enExample)
CN (1) CN111148534A (enExample)
WO (1) WO2019063802A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021032A2 (pt) * 2017-04-05 2020-05-05 Boehringer Ingelheim International Gmbh terapia combinada anticâncer
AU2020345655A1 (en) * 2019-09-11 2022-02-24 Boehringer Ingelheim Io Canada, Inc. Methods of treating cancer by the use of PD-1 axis inhibitors and anti-periostin antibodies
CN112111575B (zh) * 2020-09-22 2023-01-10 重庆医科大学附属第一医院 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AR074726A1 (es) 2008-12-12 2011-02-09 Boehringer Ingelheim Int Anticuerpos anti-igf (factor de crecimiento insulinico)
WO2013060872A1 (en) 2011-10-27 2013-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
ES2716685T3 (es) * 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
PT3096792T (pt) * 2014-01-24 2020-01-08 Boehringer Ingelheim Int Tratamento de cancro utilizando um antagonista do recetor do fator de crescimento análogo a insulina (igf) em combinação com exemestano e everolímus
UY36351A (es) * 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
US20170088609A1 (en) * 2015-09-28 2017-03-30 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2017151517A1 (en) * 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer

Similar Documents

Publication Publication Date Title
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
FI3548515T3 (fi) Radioleimattuja anti-PD-L1-vasta-aineita immuno-PET-kuvantamiseen
RU2019112029A (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
JP2013520442A5 (enExample)
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
JP2020521797A5 (enExample)
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
JP2019536806A5 (enExample)
RU2018123717A (ru) Комбинированные лечения, их применения и способы
RU2018105846A (ru) Комбинация антагониста pd-1 с ингибитором egfr
JP2017031160A5 (enExample)
JP2015532292A5 (enExample)
JP2013529183A5 (enExample)
FI3845245T3 (fi) Seerumin fosfaatin efektiivinen ja tehokas säätely optimaalista luunmuodostusta varten
JP2016502504A5 (enExample)
JP2016519650A5 (enExample)
JP2015514110A5 (enExample)
HRP20151019T1 (hr) PROTUTIJELA PROTIV c-MET
RU2018123709A (ru) Новые антитела для лечения онкологических заболеваний
RU2017136709A (ru) Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2019512472A5 (enExample)
JP2020522281A5 (enExample)
PE20160994A1 (es) Compuestos al receptor-3 del factor de crecimiento del fibroblasto (fgfr3) y metodos de tratamiento
JP2018512402A5 (enExample)